Stocklytics Platform
Asset logo for symbol VERA
Vera Therapeutics
VERA44
$42.61arrow_drop_up1.21%$0.51
Asset logo for symbol VERA
VERA44

$42.61

arrow_drop_up1.21%

Performance History

Chart placeholder
Key Stats
Open$41.66
Prev. Close$42.05
EPS-2.61
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range41.23
44.90
52 Week Range9.24
51.58
Ratios
EPS-2.61

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Vera Therapeutics (VERA)

Vera Therapeutics, Inc. (VERA) is a biopharmaceutical company focused on developing novel therapies for the treatment of serious immunological and renal diseases. The company's lead product candidate, VERA-101, is a potent small molecule inhibitor of a protein called pSTAT3, which plays a key role in the immune system and is highly expressed in certain disease states. VERA-101 has shown promising results in preclinical studies and is currently being evaluated in a phase 1 clinical trial. The company believes that targeting pSTAT3 has the potential to address unmet medical needs in a range of therapeutic areas.
In recent news, Vera Therapeutics announced positive interim data from its ongoing phase 1 study of VERA-101. The data showed that VERA-101 was well-tolerated and demonstrated dose-dependent inhibition of pSTAT3 in patients with advanced solid tumors. These results validate the company's approach and support further development of VERA-101 as a potential treatment for a variety of cancers. The company plans to advance VERA-101 into phase 2 trials in the near future.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Marshall Fordyce M.D.
Headquarters
Brisbane
Employees
49
Exchange
NASDAQ
add Vera Therapeutics to watchlist

Keep an eye on Vera Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Vera Therapeutics's (VERA) price per share?

The current price per share for Vera Therapeutics (VERA) is $42.61. The stock has seen a price change of $0.51 recently, indicating a 1.21% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Vera Therapeutics (VERA)?

For Vera Therapeutics (VERA), the 52-week high is $51.58, which is 21.06% from the current price. The 52-week low is $9.24, the current price is 361.15% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Vera Therapeutics (VERA) a growth stock?

Vera Therapeutics (VERA) has shown an average price growth of -4.97% over the past three years. It has received a score of 86 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vera Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Vera Therapeutics (VERA) stock price performance year to date (YTD)?

As of the latest data, Vera Therapeutics (VERA) has a year-to-date price change of 172.97%. Over the past month, the stock has experienced a price change of -11.8%. Over the last three months, the change has been -4.38%. Over the past six months, the figure is 22.13%.
help

Is Vera Therapeutics (VERA) a profitable company?

Vera Therapeutics (VERA) has a net income of -$95.99M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.86M, although specific revenue growth data is currently not available. The gross profit is $1.86M. Operating income is noted at -$102.01M. Furthermore, the EBITDA is $0.
help

What is the market capitalization of Vera Therapeutics (VERA)?

Vera Therapeutics (VERA) has a market capitalization of $2.7B. The average daily trading volume is 42.78, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level